IAS: Novel HIV Drug Looks Promising

The investigational next-generation non-nucleoside reverse transcriptase inhibitor lersivirine controls HIV as well as standard-care efavirenz (Sustiva) in treatment-naive patients, researchers said.
MedPage Today